In last trading session, 4D Molecular Therapeutics Inc (NASDAQ:FDMT) saw 0.32 million shares changing hands with its beta currently measuring 2.93. Company’s recent per share price level of $26.38 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $1.35B. That closing price of FDMT’s stock is at a discount of -37.41% from its 52-week high price of $36.25 and is indicating a premium of 64.22% from its 52-week low price of $9.44. Taking a look at company’s average trading volume volume of 1.20 million if we extend that period to 3-months.
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
In the last five days FDMT remained trading in the green while hitting it’s week-highest on Friday, 05/03/24 when the stock touched $26.38 price level, adding 5.24% to its value on the day. 4D Molecular Therapeutics Inc’s shares saw a change of 30.21% in year-to-date performance and have moved 13.46% in past 5-day. 4D Molecular Therapeutics Inc (NASDAQ:FDMT) showed a performance of -4.56% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
Statistics highlight that 4D Molecular Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 147.00% of value to its shares in past 6 months, showing an annual growth rate of -17.44% while that of industry is 11.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -72.20% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 780k for the same. And 6 analysts are in estimates of company making revenue of 760k in the next quarter. Company posted 298k and 850k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -46.35% during past 5 years.
FDMT Dividends
4D Molecular Therapeutics Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
